Clinical Outcomes of Descemet's Membrane Endothelial Keratoplasty: A 1-Year Retrospective Study.
10.3341/jkos.2015.56.10.1489
- Author:
Gyu Le HAN
1
;
Joo HYUN
;
Dong Hui LIM
;
Eui Sang CHUNG
;
Tae Young CHUNG
Author Information
1. Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. tychung@skku.edu
- Publication Type:Original Article
- Keywords:
Cornea;
DMEK;
Endothelial keratoplasty
- MeSH:
Astigmatism;
Cornea;
Corneal Transplantation*;
Descemet Membrane*;
Endothelial Cells;
Humans;
Korea;
Medical Records;
Reoperation;
Retrospective Studies*;
Transplants;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2015;56(10):1489-1496
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the 1-year results of Descemet's membrane endothelial keratoplasty (DMEK) in Korea. METHODS: The medical records of 9 patients (10 eyes) with endothelial disease who underwent DMEK from January 2012 to December 2013, and were followed up for more than 12 months were reviewed retrospectively. RESULTS: In 8 eyes with successful results after surgery, best corrective visual acuity (BCVA) was significantly improved from 1.64 +/- 0.21 (log MAR, mean) to 0.35 +/- 0.22 at 1 month and was maintained at 12 months (p = 0.012, Wilcoxon signed ranks test). BCVA at postoperative 3, 6 and 12 months were gradually increased (0.25 +/- 0.23, 0.20 +/- 0.17 and 0.16 +/- 0.17 log MAR). Endothelial cell counts were 1,996 +/- 528/mm2, 1,564 +/- 174/mm2 and 1,463 +/- 541/mm2, 1,205 +/- 358/mm2 at 1, 3, 6, and 12 months after surgery, tended to decrease but showed no statistical significance. There was no statistical difference in astigmatism before and 3 months after the operation (3.32 +/- 2.36 diopter and 2.57+/- 1.44 diopter). Primary graft failure occurred in 2 eyes and 1 received reoperation. Total detachment was found in 1 eye. CONCLUSIONS: The 1-year results of DMEK showed fast visual recovery which was maintained for 12 months. DMEK may be a very efficient option for the surgical management of corneal endothelial disease.
